(Q45238276)
Statements
1 reference
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations (English)
1 reference
Kazuhiro Asami
1 reference
Tomohisa Okuma
1 reference
Tomonori Hirashima
1 reference
Masaaki Kawahara
1 reference
Shinji Atagi
1 reference
Tomoya Kawaguchi
1 reference
Kyoichi Okishio
1 reference
Naoki Omachi
1 reference
Naoko Takeuchi
1 reference
20 December 2012
1 reference
1 reference
79
1 reference
3
1 reference
276-282
1 reference
Identifiers
1 reference
1 reference